36.70

78.33% 16.12

Pre-market: 36.74 0.04 +0.11%

Forte Biosciences Inc (FBRX)

Overview News Price History Option Chain Financials Discussions Forecast

Forte Biosciences Inc stock is traded at $36.70, with a volume of 4.83M. It is up +78.33% in the last 24 hours and up +115.88% over the past month. Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.

Previous Close:

$20.58

Open:

$21.25

24h Volume:

4.83M

Relative Volume:

11.51

Market Cap:

$751.57M

Revenue:

Net Income/Loss:

$-75.86M

P/E Ratio:

-7.1864

EPS:

-5.1069

Net Cash Flow:

$-59.39M

1W Performance:

+75.43%

1M Performance:

+115.88%

6M Performance:

+53.69%

1Y Performance:

+194.07%

1-Day Range:

$21.25

$37.58

1-Week Range:

$19.95

$37.58

52-Week Range:

$9.10

$37.58

Forte Biosciences Inc Stock (FBRX) Company Profile

Name

Forte Biosciences Inc

Sector

Healthcare (1100)

Industry

Biotechnology (614)

Phone

(310) 618-6994

Address

3060 PEGASUS PARK DRIVE, DALLAS, CA

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

FBRX's Discussions on Twitter

Compare FBRX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FBRX Forte Biosciences Inc	36.70	751.57M	0	-75.86M	-59.39M	-5.1069
VRTX Vertex Pharmaceuticals Inc	496.50	126.01B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	667.95	70.03B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	909.49	56.56B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	312.79	41.76B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	191.13	40.63B	742.00K	-1.37B	-1.07B	-7.0731

Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-25-25	Initiated	Evercore ISI	Outperform
Aug-18-25	Initiated	Guggenheim	Buy
Jan-21-25	Initiated	TD Cowen	Buy
Apr-08-24	Upgrade	Ladenburg Thalmann	Neutral → Buy
Sep-20-21	Upgrade	Chardan Capital Markets	Sell → Buy
Sep-03-21	Downgrade	B. Riley Securities	Buy → Neutral
Sep-03-21	Downgrade	Chardan Capital Markets	Buy → Sell
Sep-03-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Sep-03-21	Downgrade	Truist	Buy → Hold
May-14-21	Initiated	B. Riley Securities	Buy
Mar-26-21	Initiated	Citigroup	Buy
Aug-28-20	Upgrade	Chardan Capital Markets	Neutral → Buy
Aug-25-20	Initiated	Truist	Buy

View All

Forte Biosciences Inc (FBRX)

Forte Biosciences Inc Stock (FBRX) Company Profile

Compare FBRX vs VRTX, REGN, ARGX, ALNY, RVMD

Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades

Forte Biosciences Inc Stock (FBRX) Latest News

Forte Biosciences skin pigmentation disorder drug shows strong efficacy, safety in early study - MSN

FBRX Stock Explodes Higher On Surging Momentum - timothysykes.com

Enovix, Forte Biosciences rally premarket; PepsiCo slips By Investing.com - Investing.com South Africa

Market movers: Forte Biosciences, Micron Technology, Simply Good Foods, PepsiCo… - Proactive financial news

Forte Biosciences shares surge after positive phase 1b vitiligo results - Yahoo Finance

FBRX Stock On Track For Biggest Single-Day Gains In 20 Months – What’s Behind The Super Rally? - TradingView

Forte Biosciences Skin Pigmentation Disorder Drug Shows Strong Efficacy, Safety In Early Study - Benzinga

Forte Bio surges on trial data for vitiligo drug (FBRX:NASDAQ) - Seeking Alpha

Forte Biosciences Shares Climb After Positive Phase 1b Vitiligo Trial Results (FBRX) - Yahoo Finance

Forte Biosciences’ FB102 Shows Statistically Significant Improvement in Vitiligo in Phase 1b Trial With Strong Safety Profile – Minichart - Minichart

Forte Biosciences Reports Positive Phase 1b Vitiligo Results - TipRanks

Forte Biosciences reports positive phase 1b vitiligo trial results - Investing.com

Forte Biosciences stock jumps on positive vitiligo trial data - Investing.com

Forte Biosciences reports positive Phase 1b vitiligo data for FB102 with 29.6% mean FVASI improvement - TradingView

[8-K] Forte Biosciences, Inc. Reports Material Event - Stock Titan

Forte’s skin-disease drug showed measured gains through week 24 - Stock Titan

Federated Hermes (FBRX) shows 2.11M-share, 10.31% Schedule 13G/A stake - Stock Titan

Certain Options of Forte Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 8-JUL-2026. - marketscreener.com

Forte Biosciences Inc focuses on dermatology pipeline as investors weigh long-term prospects - AD HOC NEWS

FRTX to Acquire Crinetics Pharmaceuticals for $10 Billion - GuruFocus

RSU vesting boosts holdings at Forte Biosciences (NASDAQ: FBRX) - Stock Titan

FBRXForte Biosciences Inc Options - Finviz

(FBRX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Enterprise value to EBIT forward of Forte Biosciences, Inc. – NASDAQ:FBRX - TradingView

Forte Biosciences, Inc.(NasdaqCM:FBRX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Forte Biosciences, Inc.(NasdaqCM: FBRX) added to Russell 2500 Growth Benchmark - marketscreener.com

Forte Biosciences, Inc.(NasdaqCM: FBRX) added to Russell 2000 Index - marketscreener.com

Forte Biosciences, Inc.(NasdaqCM:FBRX) added to Russell Microcap Growth Benchmark Index - marketscreener.com

Forte Biosciences, Inc.(NasdaqCM: FBRX) added to Russell 2000 Growth Benchmark - marketscreener.com

Forte Biosciences, Inc.(NasdaqCM: FBRX) added to Russell 3000E Growth Benchmark - marketscreener.com

Forte Biosciences, Inc.(NasdaqCM: FBRX) added to Russell Small Cap Completeness Index - marketscreener.com

Forte Biosciences, Inc.(NasdaqCM: FBRX) dropped from Russell 3000E Value Benchmark - marketscreener.com

FBRX Q1 2026 Earnings: EPS Misses Estimates, No Revenue Reported, Stock Gains 2.15%Earnings Deceleration Risk - dars.gov.et

Forte Biosciences Inc (FBRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Forte Biosciences Inc (FBRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Forte Biosciences Inc (FBRX) Valuation: PE, PB & Fair Value Analysis - TradingKey

Forte Biosciences Inc (FBRX) Institutional Confidence - TradingKey

Forte Biosciences Inc (FBRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Forte Biosciences (FBRX) CFO receives 22,000 stock options grant - Stock Titan

Forte Biosciences (FBRX) awards 500,000 stock options to insider Wagner - Stock Titan

Forte Biosciences Inc (FBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Forte Biosciences Inc (FBRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Forte Biosciences Inc (FBRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Forte Biosciences (FBRX) Dips Nearly 5%: Testing Key Support at $16.29Revenue Weighted - newsline.com

One Forte Biosciences Insider Raised Stake By 30% In Previous Year - Yahoo Finance

[EFFECT] Forte Biosciences, Inc. SEC Filing - Stock Titan

FBRX Q1 2026 Earnings: Wider-than-Expected Loss as Biotech Continues DevelopmentMargin Guidance - newsline.com

Trading Systems Reacting to (FBRX) Volatility - Stock Traders Daily

Forte Biosciences (FBRX) Gains 5%: Support and Resistance Levels in FocusWave Extension - dars.gov.et

Millennium Group (FBRX) reports shared control of 1,062,182 shares - Stock Titan

Forte Biosciences | S-3/A: Registration statement for specified transactions by certain issuers (Amendment) - Moomoo

Forte Biosciences Inc Stock (FBRX) Financials Data

Revenue

Net Income

Cash Flow

EPS

Similar to FBRX